Small-molecule compounds target paraptosis to improve cancer therapy

Biomed Pharmacother. 2019 Oct:118:109203. doi: 10.1016/j.biopha.2019.109203. Epub 2019 Jul 12.

Abstract

According to its different occurrence mechanism, programmed cell death (PCD) is divided into apoptosis, autophagy, necrosis, paraptosis and so on. Paraptosis is morphologically different from apoptosis and autophagy, which exhibit cytoplasmic vacuolation derived from the ER, independent of caspase, absence of apoptotic morphology. Recent researches have implied that a variety of small molecule compounds, such as celastrol, curcumin, can induce paraptosis-associated cell death as the reagent to enhance anti-cancer activity. A better understanding of paraptosis will lay the foundation to develop new therapeutic strategies to treat human cancers that make full use of small-molecule compounds.

Keywords: Cancer therapy; Paraptosis; Programmed cell death; Small-Molecule compounds.

Publication types

  • Review

MeSH terms

  • Animals
  • Apoptosis / drug effects
  • Autophagy / drug effects
  • Biological Products / chemistry
  • Biological Products / pharmacology*
  • Cell Line, Tumor
  • Endoplasmic Reticulum / drug effects
  • Endoplasmic Reticulum / metabolism
  • Humans
  • Neoplasms / drug therapy*
  • Neoplasms / metabolism
  • Neoplasms / pathology
  • Protein Biosynthesis / drug effects
  • Regulated Cell Death / drug effects*
  • Small Molecule Libraries / chemistry
  • Small Molecule Libraries / pharmacology*
  • Vacuoles / drug effects
  • Vacuoles / metabolism

Substances

  • Biological Products
  • Small Molecule Libraries